SCHEMBL3404054

SCHEMBL3404054

NS(=O)(=O)c1ccc(NC(=S)N(Cc2ccccn2)Cc2ccccn2)cc1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.65
CA1 P00915 4/20 0.65
CA5A P35218 1/20 0.62
CA7 P43166 1/20 0.62
CA5B Q9Y2D0 1/20 0.62
MAPT P10636 5/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
NPSR1 Q6W5P4 2/20 0.60
HTT P42858 1/20 0.60
CA9 Q16790 1/20 0.55
ALDH1A1 P00352 7/20 0.54
GAA P10253 2/20 0.50
PTPN7 P35236 1/20 0.50
PKM P14618 1/20 0.50
RECQL P46063 2/20 0.49
POLB P06746 2/20 0.47
LMNA P02545 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13769050 0.81 MAPT (0.66) MAPTSMN1; SMN2NPSR1HTTALDH1A1
SCHEMBL13764466 0.77 CA2 (0.49) CA2CA1CA5ACA7CA5B
SCHEMBL2839421 0.77 CA1 (0.69) CA2CA1CA5ACA7CA5B
SCHEMBL2474574 0.77 CA1 (0.69) CA2CA1CA5ACA7CA5B
SCHEMBL3404091 0.76 CA2 (0.56) CA2CA1CA5ACA7CA5B
SCHEMBL2830813 0.74 CA2 (0.64) CA2CA1CA5ACA7CA5B
SCHEMBL18059017 0.74 CA2 (0.64) CA2CA1CA5ACA7CA5B
SCHEMBL2835965 0.74 CA1 (0.66) CA2CA1CA5ACA7CA5B
SCHEMBL11646781 0.73 MAPT (0.72) MAPTSMN1; SMN2NPSR1HTTALDH1A1
SCHEMBL15335312 0.72 CA1 (0.62) CA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2823826-A2 Inhibitors of carbonic anhydrase IX Molecular Insight Pharmaceuticals, Inc. (US) 2015-01-14 EP disclosed
US-8877970-B2 Inhibitors of carbonic anhydrase IX MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2014-11-04 US disclosed
US-8877970-B2 Inhibitors of carbonic anhydrase IX MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2014-11-04 US disclosed
US-8877970-B2 Inhibitors of carbonic anhydrase IX MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2014-11-04 US disclosed
EP-2240171-B1 Inhibitors of carbonic anhydrase IX MOLECULAR INSIGHT PHARM INC (US) 2014-08-13 EP disclosed
EP-2240171-A2 INHIBITORS OF CARBONIC ANHYDRASE IX Molecular Insight Pharmaceuticals, Inc. (US) 2010-10-20 EP disclosed
WO-2009089383-A2 INHIBITORS OF CARBONIC ANHYDRASE IX MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2009-07-16 WO disclosed
US-20090175794-A1 INHIBITORS OF CARBONIC ANHYDRASE IX MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2009-07-09 US disclosed
US-20090175794-A1 INHIBITORS OF CARBONIC ANHYDRASE IX MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2009-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090175794-A1 INHIBITORS OF CARBONIC ANHYDRASE IX CA9, CA12, CA1 CA2 7/4885CA1 3/4885CA5A 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.